

---

**Product Data Sheet**

---

Product Name: Terazosin

Cat. No.: GC13085

**Chemical Properties**

Cas. No. 63590-64-7

Chemical Name [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone

SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OCFormula  $C_{19}H_{25}N_5O_4$  M.Wt 387.43Solubility  $\geq 38.7\text{mg/mL}$  in DMSO with gentle warming Storage Store at  $-20^{\circ}\text{C}$ General tips For obtaining a higher solubility, please warm the tube at  $37^{\circ}\text{C}$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^{\circ}\text{C}$  for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure **Background**

Terazosin is an antagonist of  $\alpha_1$ -adrenergic receptor [1].

Terazosin is a long acting and selective  $\alpha_1$ -adrenergic-antagonist drug. The major use of it is the treatment for benign prostatic hyperplasia since it can relax the prostatic smooth muscle. Terazosin is proved to be a safe and effective treatment and has few adverse effects [1].

Besides, terazosin is also used to treat for hypertension. It is found to significantly decrease blood pressure in patients with uncomplicated hypertension. It is also found to effect blood lipids beneficially. Terazosin modestly lowers blood total cholesterol, low density lipoprotein cholesterol and triglycerides as well as increases high density lipoprotein. The beneficial effects make terazosin more potent to prevent coronary heart disease [2].

References:

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

[1] Lepor H, Williford W O, Barry M J, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. *New England Journal of Medicine*, 1996, 335(8): 533-540.

[2] Grimm R H. alpha 1-antagonists in the treatment of hypertension. *Hypertension*, 1989, 13(5 Suppl): I131.

***Caution: Product has not been fully validated for medical applications. For research use only.***

***Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com***

***Address: 10292 Central Ave. #205, Montclair, CA, USA***